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Abstract
Cholesterol-lowering treatment has been suggested to delay progression of prostate cancer by decreasing serum LDL. We
studied in vitro the effect of extracellular LDL-cholesterol on the number of prostate epithelial cells and on the expression of
key regulators of cholesterol metabolism. Two normal prostatic epithelial cell lines (P96E, P97E), two in vitro immortalized
epithelial cell lines (PWR-1E, RWPE-1) and two cancer cell lines (LNCaP and VCaP) were grown in cholesterol-deficient
conditions. Cells were treated with 1–50 mg/ml LDL-cholesterol and/or 100 nM simvastatin for seven days. Cell number
relative to control was measured with crystal violet staining. Changes in mRNA and protein expression of key effectors in
cholesterol metabolism (HMGCR, LDLR, SREBP2 and ABCA1) were measured with RT-PCR and immunoblotting, respectively.
LDL increased the relative cell number of prostate cancer cell lines, but reduced the number of normal epithelial cells at
high concentrations. Treatment with cholesterol-lowering simvastatin induced up to 90% reduction in relative cell number
of normal cell lines but a 15–20% reduction in relative number of cancer cells, an effect accompanied by sharp upregulation
of HMGCR and LDLR. These effects were prevented by LDL. Compared to the normal cells, prostate cancer cells showed high
expression of cholesterol-producing HMGCR but failed to express the major cholesterol exporter ABCA1. LDL increased
relative cell number of cancer cell lines, and these cells were less vulnerable than normal cells to cholesterol-lowering
simvastatin treatment. Our study supports the importance of LDL for prostate cancer cells, and suggests that cholesterol
metabolism in prostate cancer has been reprogrammed to increased production in order to support rapid cell growth.
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Introduction
Current literature suggests that cholesterol may play an
important role in the development and progression of prostate
cancer. Several epidemiologic studies have reported a significant
positive correlation between hypercholesterolemia or dyslipidemia
and prostate cancer incidence [1–7]. Experimental studies support
these findings, as elevation of circulating cholesterol promotes
tumor growth and tumor cholesterol content in a mouse LNCaP
xenograft model [8,9], while reduction in cholesterol levels retards
prostate cancer growth, possibly by inhibition of tumor angiogen-
esis [10]. Recently, epidemiological and laboratory studies have
suggested that cholesterol-lowering statin drugs might lower the
risk of advanced prostate cancer [11].
In vitro studies have proposed that the elevated cholesterol levels
in prostate tumor cells could be due to dysregulation of the key
regulators of cholesterol homeostasis [12,13], which could have
significance in the progression of prostate cancer into androgen-
independent state [14,15]. Very little is currently known, however,
about cholesterol metabolism in normal prostatic epithelial cells
and its differences compared to cancer cells.
In the present study we evaluated the effect of cholesterol on
growth of both primary and in vitro immortalized prostate
epithelial cells, and on the growth of androgen-dependent cancer
cells. Additionally, we studied the effects of cholesterol and statin
treatment on the expression of key participants in cholesterol
metabolism: 3-hydroxy-3-methylglutaryl-Coa-reductase
(HMGCR), a rate-limiting enzyme in cholesterol-producing
mevalonate pathway; Low density lipoprotein receptor (LDLR),
required for LDL uptake; Sterol-regulatory element binding
protein 2 (SREBP2), regulator of intracellular cholesterol content
[16] and the ATP-binding cassette, subfamily A, member 1
(ABCA1), which mediates the efflux of cellular cholesterol [17].
Materials and Methods
Materials
Phenol red-free RPMI 1640, fetal calf serum (FCS), L-
glutamine, antibiotic-antimycotic solution (A/A), keratinocyte-
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SFM (K-SFM), recombinant epidermal growth factor (rEGF),
and bovine pituitary extract (BPE) were from Invitrogen
(Carlsbad, CA, USA). Simvastatin and Low Density Lipopro-
teins, Human Plasma (LDL) were purchased from Calbiochem
(Gibbstown, NJ, USA). Anti-beta-actin antibody (AC-15) was
obtained from Sigma (St. Louis, MO, USA). Anti-rabbit IgG,
Horse Radish Peroxidase (HRP) –linked antibody and anti-
mouse IgG, HRP-linked antibody were from Cell Signaling
Technology Inc. (Danvers, MA, USA). Antibody for 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR (C-1)) was from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibody for
ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1
(Clone AB.H10)) was from Millipore (Billerica, MA, USA).
Antibody for low density lipoprotein receptor (LDLR (EP1553Y))
was from Novus Biologicals, LLC (Littleton, CO, USA) and
antibody for Sterol regulatory element-binding protein 2
(SREBP2 (Clone IgG-1C6)) was from BD Biosciences (Franklin
Lakes, NJ, USA). Lipoprotein deficient serum (LPDS) was
created as described earlier [18]. CorningH CellbindH 6-well
plates were purchased from Corning (Corning, NY, USA). All
other disposable cell culture materials were from Nalge Nunc
International (Rochester, NY, USA).
Cell Lines and Culture Conditions
Generation and authentication of P96E and P97E primary
prostatic normal epithelial cell lines has been described previously
[19]. RWPE-1 and PWR-1E cells (immortalized prostate epithelial
cell lines) were a gift from VTT Technical Research Centre,
Turku, Finland. P96E, P97E, PWR-1E and RWPE-1 cells were
cultured in K-SFM supplemented with 50 mg/ml BPE, 5 ng/ml
rEGF and 1% A/A. LNCaP prostate cancer cells were from
American Type Culture Collection (Rockville, MD, USA). VCaP
prostate cancer cells were a gift from Professor T. Visakorpi, IBT
institute, University of Tampere, Finland. LNCaP and VCaP cells
were cultured in RPMI 1640 supplemented with 10% FCS, 1% L-
glutamine and 1% A/A.
For studies on cell number relative to control, 46104 (PWR-1E),
56104 (RWPE-1), 66104 (P96E, P97E and LNCaP) or 36105
(VCaP) cells per well were seeded on 6-well plates and allowed to
attach for 48 hours. LNCaP and VCaP cells were grown on
CorningH CellbindH 6-well plates, whereas normal cell lines were
grown on 6-well plates from Nalge Nunc International. After
attachment, LNCaP and VCaP cells were grown in lipid deficient
medium (RPMI 1640 supplemented with 10% LPDS, 1% L-
glutamine and 1% A/A). The normal prostate epithelial cells were
routinely grown in Keratinocyte-SFM which is serum free and
essentially lipid deficient.
The cells were treated with LDL-cholesterol or vehicle (DMSO)
for seven days. LDL-cholesterol was used in 1–50 mg/ml
concentrations to test the dose-dependence of effect. This is the
concentration range in standard cell culture conditions when 10%
fetal calf serum is being used [20]. This range also allows proper
functioning of the LDL-receptor [21]. The highest concentration
(50 mg/ml) is in the range of that found in human plasma (from
,100 mg/dl to .250 mg/dl) assuming relation 10:1 between
concentration in plasma to that of interstitial tissue.
Growth medium and drugs were renewed every other day. After
treatments, the cells were fixed, stained and their number was
assessed with modified crystal violet staining method [22].
Absorbances were measured at day 0 and day 7with a Victor
1420 Multilabel Counter (Wallac, Turku, Finland), and the value
at day 0 was subtracted from the values at day 7.
For the RNA and protein studies, the cells were seeded to
75 cm2 flasks and allowed to attach for 48 hours. After
attachment, the cells were grown in lipid deficient medium as
described above and treated with vehicle (DMSO), 100 nM
simvastatin, 50 mg/ml LDL-cholesterol or in their combination for
48 hours and then subjected to Trizol (Invitrogen, Carlsbad, CA,
USA) reagent for RNA extraction or M-PERH (PIERCE,
Rockford, IL, USA) reagent modified with protease inhibitors
(Complete Mini Protease inhibitor cocktail tablets (Roche
Diagnostics GmbH, Indianapolis, IN, USA)) for protein extraction
according to the manufacturer’s instructions.
SDS-PAGE and Western Blot
Total protein concentrations were measured using BCA Protein
Assay Kit (Pierce) according to the manufacturer’s instructions.
50 mg of total protein was mixed (1:1) with 2X Laemmli sample
buffer (Sigma, ST. Louis, MO, USA), boiled for 5 min and
analyzed by electrophoresis in 12% polyacrylamide gel (PAGE).
An exception to this, protein samples for HMGCR were not
boiled to avoid protein aggregation upon heating. Precision Plus
Protein Standards were used (Bio-Rad Laboratories, Hercules,
CA, USA). Proteins separated by PAGE were transferred (1 hour)
to the Immobilon-P polyvinylidene fluoride transfer membrane
(0.45 mm pore size) (Millipore, Billerica, MA USA) at room
temperature (RT) using NuPage transfer buffer (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
Membranes were then incubated for 1 hour at RT in Tris buffer
containing salt and Tween (TBST) (50 mM Tris-HCL, 150 mM
NaCL, 0,05% Tween 20, pH 8.0) and 5% non-fat dry milk
powder (5% milk-TBST) to saturate the non-specific protein
binding sites. Membranes were incubated with the primary
antibodies in 5% milk-TBST overnight at 4uC with mild agitation.
The membranes were washed 3 times for 5 min with TBST and
incubated for 1 hour with horse radish peroxidase -conjugated
secondary antibody in 5% milk-TBST with mild agitation at RT.
The membranes were washed 3 times for 5 min with TBST and
subjected to enhanced chemiluminescence reagents (ECL Western
Blotting Detection Reagents, GE Healthcare, Buckinghamshire,
UK) according to the manufacturer’s instructions and exposed to
X-ray film.
Real-Time RT-PCR
The RNA samples were reverse transcribed to cDNA with High
Capacity Archive Kit (Applied Biosystems, CA, USA) following
the instructions of the manufacturer. The real-time RT-PCR was
performed by using SYBR Green PCR Master Mix Kit (Applied
Biosystems) in ABI PRISM 7000 Detection System (Applied
Biosystems) according to the manufacturer’s instructions. The data
were analyzed by ABI PRISM 7000 SDS Software (Applied
Biosystems). The final results, expressed as N-fold relative
differences (ratio) in gene expression between the studied samples
and the control (i.e. calibrator) sample, were calculated according
to the following equation [15]: Ratio = ((Etarget)
DCP target (control-
sample))/((Eref)
DCP ref (control-sample)). Etarget is the real-time PCR
efficiency of target gene transcript; Eref is the real-time PCR
efficiency of a reference gene transcript; DCPtarget is the CP
(crossing point) deviation of control – sample (subtraction) of the
target gene transcript; DCPref is the CP deviation of control –
sample of reference gene (Beta-actin) transcript. Real-time PCR
efficiencies (E) were calculated, according to E= 10[-1/slope].
Following primers (TAG, Copenhagen, Denmark) were used:
HMGCR forward primer (f) 59- GGC TGC AGA GCA ATA
GGT CTT G -39 and HMGCR reverse primer (r) 59- CAC GTG
GAA GAC GCA CAA CT -39. LDLR (f) 59- AGT TGG CTG
CGT TAA TGT GAC A -39 and LDLR (r) 59- CTC TAG CCA
TGT TGC AGA CTT TGT -39. SREBP2 (f) 59- CAA GTC
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TGG CGT TCT GAG GAA -39 and SREBP2 (r) 59- GCC CTT
TAG AAG CTT GTT CTT TTG -39. ABCA1 (f) 59- GAG CAC
CAT CCG GCA GAA -39 and ABCA1 (r) 59- CTC CGC CTT
CAC GTG CTT -39. Beta-actin (f) 59-CCA GCT CAC CAT
GGA TGA TG -39 and Beta-actin (r) 59- ATG CCG GAG CCG
TTG TC -39. The primers were designed using Primer Express
software for ABI PRISM 7000 detection system (Applied
Biosystems).
Statistical Analysis
All experiments were repeated separately three times. The
median, the highest and the lowest values are reported for each
treatment. The non-parametric Mann-Whitney U-test was used to
analyze the statistical significance of differences in the outcome
measurements between treatments. All p-values are two-sided.
Results
LDL, Simvastatin and Cell Number
The response in cell number relative to control to increasing
concentrations of LDL-cholesterol differed between cancer cells
and primary or transformed prostate epithelial cells (Fig.1). High
concentrations (30 and 50 mg/ml) of LDL-cholesterol clearly
reduced the number of primary cells. However, only slight
reduction in the relative cell number was observed in PWR-1E
when the highest concentration of LDL-cholesterol (50 mg/ml)
was used. On the other hand, relative cell number of both cancer
cell lines was slightly stimulated by LDL-cholesterol at the highest
concentrations (Fig.1).
Both 100 nM simvastatin and 50 mg/ml LDL-cholesterol
reduced the number of normal epithelial cells, with the exception
of PWR-1E (Fig. 2). LDL-cholesterol attenuated the relative cell
number reduction caused by simvastatin in P96E and P97E cells
(p,0.05 for difference between combination of simvastatin and
LDL treatment as compared to simvastatin alone), although the
reduction relative to control cells remained significant. Compared
to the control, addition of LDL to simvastatin removed the
significant relative cell number decreasing effect of simvastatin
alone in RWPE-1 cells, although the difference between the two
treatments remained non-significant. In cancer cell lines simvas-
tatin caused only modest reduction in relative cell number, an
effect fully compensated by LDL-cholesterol (Fig 2). Simvastatin
slightly reduced the relative cell number increasing effect of LDL-
cholesterol on cancer cells.
Expression of Cholesterol Metabolizing Factors at
Baseline
The basal protein expression levels of important regulators of
cellular cholesterol metabolism in a standard amount of protein
were compared between normal epithelial cells and cancer cell
lines after the cells had been grown in cholesterol-deficient
medium for seven days. All cell lines expressed SREBP2 at protein
level, cancer cell lines more strongly than normal cell lines (Fig. 3a,
suppl. Fig S1), although the mRNA expression did not differ
greatly between the cell lines (Fig 3b). The exception was RWPE-
1, where mRNA expression of SREBP2 was low compared to any
other cell line.
Under these circumstances the cancer cell lines exhibited
upregulation of HMGCR at protein level, suggesting increased
cholesterol production, whereas normal primary cells showed
upregulation of LDLR (Fig 3a, suppl. Fig S1). Again, baseline
mRNA expression differed from protein expression as both
HMGCR and LDLR expression were markedly higher in normal
primary cells P96E and P97E as compared to cancer cell lines
(Fig 3b). In PWR-1e and RWPE-1 the mRNA expressions were
similar to cancer cell lines.
Even under depletion of extracellular cholesterol, the normal
epithelial cells (with the exception of PWR-1E) expressed
cholesterol transporter ABCA1 at protein level, whereas cancer
cell lines did not (Fig. 3a, suppl. Fig S1). For ABCA1 The mRNA
expression was similar to protein expression: high expression in
normal cell lines P96E, P97E and RWPE-1, but almost no
expression in cancer cell lines and PWR-1e (Fig 3b).
Figure 1. A dose-dependent effect of cholesterol on relative cell number of prostate epithelial cell lines. Number of the treated cells
was compared relative to the respective untreated (0) cells after seven days treatment. Results represent the median (bar), lowest and highest (error
bars) results of three independent experiments. *p,0.04.
doi:10.1371/journal.pone.0039445.g001
Cholesterol and Prostate Cancer
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Effect of LDL and Simvastatin on the Expression of Key
Cholesterol-metabolizing Factors
Inhibition of de novo cholesterol synthesis with simvastatin
sharply upregulated the mRNA (Fig. 4 a and b) and protein
expressions of HMGCR and LDLR (Fig. 4c and d) in all cell lines.
Simvastatin also upregulated mRNA expression of SREBP2
(Fig. 5b). At protein level simvastatin treatment did not increase
SREBP2 expression, but rather caused cleavage of the protein into
125 kDa and 60 kDa bands (Fig. 5d). In normal cells the
expression of ABCA1 was clearly down-regulated by simvastatin
(Fig. 5a and c). In cancer cells simvastatin did not markedly affect
ABCA1 expression (Fig. 5a and c).
Compared to control, LDL-cholesterol downregulated
HMGCR mRNA expression significantly only in P97E, while
downregulation of protein expression was most clearly observed in
cancer cell lines LNCaP and VCaP (Fig 4 a and c). LDL also
downregulated LDLR mRNA expression in P97E and LNCaP
(Fig 4b), but protein expression was downregulated in all cell lines
except P96E (Fig. 4d). The response in ABCA1 differed between
cancer cells and normal cells: availability of extracellular LDL
upregulated ABCA1 in the normal cell lines, but the cancer cells
did not express this transporter at detectable protein level even
after LDL-cholesterol treatment, although slight changes were
observed in mRNA expression (Fig. 5a and c). LDL decreased the
mRNA expression of SREBP2 in P97E, but in other cell lines the
expression was comparable to vehicle-treated cells (Fig. 5b). At
protein level LDL prevented the effect of simvastatin on cleavage
of SREBP2 into two bands in P96E, P97E and RWPE-1 (Fig 5d).
LDL prevented most of the effects of simvastatin on the
expression of cholesterol metabolizing factors (Fig. 4a-d and Fig 5a-
d). An exception was HMGCR in the LNCaP, where simvastatin
caused upregulation of the enzyme expression even in the presence
of LDL (Fig. 4a and c).
Discussion
Our observations support the importance of cholesterol for the
growth of prostate cancer cell lines: 1) increase in cell number
relative to control after treatment with increasing concentrations
of LDL; 2) decreased relative cell number after inhibition of
intracellular cholesterol synthesis with simvastatin, which could be
prevented by addition of LDL; 3) enhanced expression of HMG-
CoA reductase, the rate-limiting enzyme of cholesterol biosynhesis
at baseline in cancer cell lines and 4) no evidence of ABCA1
expression in cancer cells under any circumstances, even after
LDL treatment.
Cholesterol is important for cell membrane integrity and
cellular metabolism, as well as for signalling pathways essential
for cellular proliferation, such as PI3K/Akt [23]. Combined, our
results suggest that LDL is needed for growth of prostate cancer
cells. Increased expression of the biosynthetic machinery along
with no expression of the major participant in cholesterol efflux
from the cells suggests reprogramming of cholesterol metabolism
in cancer cells. Although remaining responsive to changes in
extracellular conditions such as treatment with simvastatin or
LDL, the metabolism has been geared towards providing the cells
with maximal supply of cholesterol to enable rapid cell growth
under any conditions. Even in cholesterol-free conditions in-
hibition of intracellular cholesterol synthesis with simvastatin
reduced the number of cancer cells 15–20%, but up to 90% of
normal epithelial cells; presumably higher baseline cholesterol
synthesis protects cancer cells against the effects of simvastatin.
However, we did not directly measure intracellular cholesterol
synthesis.
Besides cholesterol, mevalonate pathway produces also iso-
prenoids farnesylpyrophosphate (FPP) and geranylgeranylpyro-
phosphate (GGPP), which in turn have important cell growth
regulatory functions [24]. Inhibition of these end-products of
mevalonate pathway and resulting cellular changes are termed
Figure 2. The effect of simvastatin (Sim), LDL-cholesterol (LDL) or combination (Sim + LDL) on cell number relative to control. The
cell lines were treated with 100 nM Sim, 50 mg/ml LDL or in combination for seven days. Number of the treated cells was compared relative to the
respective untreated control (C) cells. Results represent the median (bar), lowest and highest (error bars) results of three independent experiments.
*p,0.04.
doi:10.1371/journal.pone.0039445.g002
Cholesterol and Prostate Cancer
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pleiotropic effects of statins. The differing ability of LDL to restore
the relative cell number reduction caused by simvastatin between
the cell lines could have been due to differing role of pleiotropic
effects. In future the relationship between inhibition of isoprenoid
production and cholesterol production when studying statins’
effects on cell growth should be further studied.
The relative cell number of normal epithelial cell lines was not
induced by LDL, but conversely high concentrations caused
reduction. Normal cells also require cholesterol for cell growth as
treatment with simvastatin caused a powerful growth inhibition,
again restored by addition of LDL. Normal cells responded to
simvastatin treatment by increasing HMGCR and LDLR
expressions, but unlike the cancer cell lines, normal cells also
increased expression of cholesterol exporting transporter ABCA1
as a result of treatment with LDL. This suggests that normal cells
need equilibrium in cholesterol homeostasis for undisturbed cell
growth. The changes in normal cells reflect attempts to adapt to
Figure 3. Basal protein expression (a) and mRNA expression (b)
of HMG-CR, LDLR, ABCA1 and SREBP2 in prostate epithelial
cell lines. All cell lines were grown in lipid-deficient medium. A protein
band of 90 kilodaltons (kDa) is shown for HMG-CR and a 254 kDa band
for ABCA1. A double band of 120 and 100 kDa is shown (arrows) for
LDLR. For SREBP2, the 125 kDa precursor and 60 kDa cleaved mature
form is shown (arrows). *p,0.04.
doi:10.1371/journal.pone.0039445.g003
Figure 4. Analysis of HMG-CR and LDLR in prostate epithelial
cell lines. The mRNA levels measured by RT-PCR (a and b) and protein
levels by Western blotting (c and d). Beta-actin expression is reported in
e). The cell lines were treated with DMSO (C) 100 nM Sim (Sim), 50 mg/
ml LDL-cholesterol (LDL) or in combination (Sim + LDL) for 48 hours. A
double band of 120 and 100 kilodaltons (kDa) is shown (arrows) for
LDLR and a 90 kDa band for HMG-CR. The HMG-CR and LDLR mRNA
expression levels were calculated relative to the DMSO-treated (C)
samples. RT-PCR results represent the median (bar), lowest and highest
(error bars) results of three independent experiments. *p,0.04.
doi:10.1371/journal.pone.0039445.g004
Cholesterol and Prostate Cancer
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changing extracellular conditions by adjusting intracellular cho-
lesterol metabolism to maintain the equilibrium. Very high LDL
concentrations, however, likely exceed this adaptive potential,
causing toxic growth inhibition. Such was not observed in cancer
cell lines, however. These differences between normal prostatic
epithelial cells and cancer cell lines reflect the changes in
cholesterol metabolism occurring during carcinogenesis in the
prostate. Likely reprogramming of cholesterol metabolism is
a crucial part of the rearrangement of energy metabolism in
cancer cells supporting constant proliferation [25], a trait that has
been recognized as one of the hallmarks of cancer [26].
Also in previous studies cholesterol has increased the growth of
prostate cancer cell lines PC3 and DU-145 [27,28]. Unlike in our
study LDL treatment has not been previously found to induce
growth of LNCaP cells [29], despite similar downregulation of
LDLR expression. The discrepancy in the results is possibly
explained by the shorter duration of LDL treatment in the
previous study (48 h) compared to ours (seven days). In this paper
we focused on effects of LDL to further explore the association
with prostate cancer risk reported in epidemiological studies [7,30]
and observed in our previous studies [31]. Nevertheless, also high-
density lipoprotein (HDL) has been reported to induce prostate
cancer cell growth [32], suggesting that cancer cells can probably
use various types of lipoproteins as a source of cholesterol.
The importance of cholesterol for prostate cancer growth is
further supported by experimental studies, where elevation of
circulating cholesterol has been reported to increase tumor growth
and intra-tumoral cholesterol accumulation in a mouse LNCaP
xenograft model [8,9], PC-3 xenograft [27] and DU-145 xenograft
[33]. A hypercholesterolemic diet changes prostate morphology in
male Wistar rats [34]. On the other hand, reducing cholesterol
levels retards prostate cancer growth possibly by inhibition of
tumor angiogenesis in a prostate cancer xenograft model [10].
Changes in the expression levels of the key regulators of
cholesterol homeostasis, namely sterol regulatory element binding
transcription factors (SREBPs), HMGCR LDLR, acetyl-CoA
acetyltransferase 1 (ACAT1) and scavenger receptor class B
member 1 (SR-B1) have been shown to occur during the
progression of prostate cancer from androgen-independent to
castration-resistant cancer in an LNCaP xenograft model [14,15].
Cholesterol influx by SR-B1 is essential for viability of prostate
cancer cell lines such as LNCaP [35]. We have demonstrated that
marked differences in expression of key regulators of cholesterol
metabolism are observed already between normal epithelial cell
lines and androgen responsive LNCaP and VCaP cancer cell lines.
Nevertheless, cholesterol metabolism remains responsive to
extracellular stimuli; our results are in concordance with a previous
study by Krycer et al [13] reporting feedback regulation of
SREBP2, HMGCR and LDLR mRNA expression in cancer cells
and normal epithelial cells by extracellular cholesterol. We further
show that this regulation occurs at protein level, and also in
primary normal prostate epithelial cells which have been isolated
directly from prostatic tissues. The differences observed between
mRNA and protein expressions of HMGCR, LDLR and SREBP2
suggests that mRNA of these enzymes may undergo posttransla-
tional modifications before transcription into protein level. Further
research will be needed.
In vivo evidence for the importance of cholesterol in prostate
cancer progression comes from epidemiological studies reporting
increased risk of advanced prostate cancer among hypercholes-
terolemic men [1,2]. Serum cholesterol decreases spontaneously
within nine years before a cancer diagnosis [3], which might
indicate that a developing tumor consumes cholesterol from the
circulation to enable cell growth; a notion supported by some in
Figure 5. Analysis of ABCA1 and SREBP2 in prostate epithelial
cell lines. The mRNA levels measured by RT-PCR (a and b) and protein
levels by Western blotting (c and d). Beta-actin expression is reported in
e). The cell lines were treated with DMSO (C) 100 nM Sim (Sim), 50 mg/
ml LDL-cholesterol (LDL) or in combination (Sim + LDL) for 48 hours. A
double band of 125 kilodaltons (kDa) (precursor form) and 60 kDa
(cleaved form) is shown (arrows) for SREBP2 and a 254 kDa band for
ABCA1. The ABCA1 and SREBP2 mRNA expression levels were calculated
relative to the DMSO-treated (C) samples. RT-PCR results represent the
median (bar), lowest and highest (error bars) results of three
independent experiments. *p,0.04.
doi:10.1371/journal.pone.0039445.g005
Cholesterol and Prostate Cancer
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vitro studies [36]. Improved recurrence-free survival after radical
treatment of prostate cancer has been reported among men using
cholesterol-lowering statin drugs, an association possibly related to
serum LDL decrease during statin therapy [37].
We could not test the responses of early-stage prostate cancer
cells to LDL and statin treatments as these are not currently
commercially available. However, it could be reasonably pre-
sumed that the responses of well-differentiated prostate cancer
cells at the early stages of carcinogenesis resemble those of normal
epithelial cells. In our study the cells were grown in monolayer
cultures, whereas in vivo prostate epithelial cells are in close contact
with the surrounding stroma, which has important functions in
carcinogenesis [26] and could modify epithelial cells’ responses to
LDL and simvastatin. Thus in vivo studies will be needed to
confirm our findings.
We have shown that increasing doses of LDL induce number of
prostate cancer cells, but not normal epithelial cells. Both normal
and cancer cells increase the production of effectors that ensure
the synthesis and uptake of cholesterol under depletion, but cancer
cells do not express the major exporter of cholesterol, ABCA1
even in the abundance of LDL. Cholesterol availability is likely an
important prerequisite for prostate cancer growth and cholesterol
metabolism in prostate cancer cells is reprogrammed to supply the
cells with abundance of cholesterol. Cholesterol-lowering might
prove to be a good strategy to prevent and delay prostate cancer
progression. Hypercholesterolemia as an etiologic factor for
prostate cancer deserves further studies.
Supporting Information
Figure S1 Quantification of relative intensities of im-
munoblotted bands shown in Fig 3. Relative intensities of
bands on Western blots were quantified using ImageJ 1.45 (http://
imagej.nih.gov/ij/) according to instructions by Luke Miller
available in http://lukemiller.org/index.php/2010/11/
analyzing-gels-and-western-blots-with-image-j/with minor modifi-
cations. Shortly, band density for a given protein in different cell
types was divided with that of P96E cells, to obtain relative
densities of bands. The relative densities in P96E cells represent
the value 1. Values below 0.1 are denoted,0.1. Cases in which no
band was detected are denoted as n.d. (not detected).
(DOC)
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